Brief communication: Ramipril markedly improves walking ability in patients with peripheral arterial disease - A randomized trial

Annals of Internal Medicine

Volumn 144, Issue 9, 2006, Pages 660-664

  Ahimastos, Anna A ^a,b   Lawler, Adam ^a,c   Reid, Christopher M ^a,d   Blombery, Peter A ^a,c   Kingwell, Bronwyn A ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c ALFRED HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; PLACEBO; RAMIPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ABSENCE OF SIDE EFFECTS; AGED; ANAMNESIS; ANKLE BRACHIAL INDEX; ARTERY DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; ECHOGRAPHY; FEMALE; HUMAN; HYPERTENSION; MALE; PHYSICAL CAPACITY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREADMILL EXERCISE; TREATMENT OUTCOME; WALKING; BLOOD FLOW; BLOOD PRESSURE; EXERCISE; INTERMITTENT CLAUDICATION; MIDDLE AGED; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; DOUBLE-BLIND METHOD; EXERCISE; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; QUESTIONNAIRES; RAMIPRIL; REGIONAL BLOOD FLOW; WALKING;

EID: 33646445060     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-144-9-200605020-00009     Document Type: Article

References (20)

1. Newman AB. Peripheral arterial disease: insights from population studies of older adults. J Am Geriatr Soc. 2000;48:1157-62.
2. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-53.
3. O'Keefe JH, Wetzel M, Moe RR, Bronsnahan K, Lavie CJ. Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease? J Am Coll Cardiol. 2001;37:1-8.
4. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation. 1996;94:258-65.
5. Sumner DS, Strandness DE Jr. The relationship between calf blood flow and ankle blood pressure in patients with intermittent claudication. Surgery. 1969;65:763-71.
6. Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaluation of walking impairment by questionnaire in patients with peripheral arterial disease. Journal of Vascular Medicine and Biology. 1990;2:142-52.
7. Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical trials for claudication. Assessment of exercise performance, functional status, and clinical end points. Vascular Clinical Trialists. Circulation. 1995;92:614-21.
8. Nehler MR, Hiatt WR. Exercise therapy for claudication. Ann Vasc Surg. 1999;13:109-14.
9. Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA. 1995;274:975-80.
10. Beebe HG, Dawson DL, Cutler BS, Herd JA, Strandness DE Jr, Bortey EB, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med. 1999;159:2041-50.
11. Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-30.
12. Sonecha TN, Nicolaides AN, Kyprianou P, Zukowski A, Papadakis K, Vasdekis S, et al. The effect of enalapril on leg muscle blood flow in patients with claudication. Int Angiol. 1990;9:22-4.
13. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol, and pindolol in hypertension complicated by intermittent claudication. Lancet. 1987;2:650-3.
14. Roberts DH, Tsao Y, Linge K, McLoughlin GA, Breckenridge A. Doubleblind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication. Angiology. 1992;43:748-56.
15. Bernardi D, Bartoli P, Ferreri A, Geri AB, Ieri A. Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using Doppler ultrasound. Angiology. 1988;39:942-52.
16. Van de Ven LL, Van Leeuwen JT, Smit AJ. The influence of chronic treatment with betablockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa. 1994;23:357-62.
17. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol. 2000;35:284-91.
18. Fabre JE, Rivard A, Magner M, Silver M, Isner JM. Tissue inhibition of angiotensin-converting enzyme activity stimulates angiogenesis in vivo. Circulation. 1999;99:3043-9.
19. Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. Circ Res. 2001;89:678-83.
20. Brewster DC. Direct reconstruction for aorto-iliac occlusive disease. In: Rutherford RB, ed. Vascular Surgery. 5th ed. Philadelphia: WB Saunders; 2000.